Jentadueto is a fixed-dose combination tablet that pairs linagliptin (a DPP-4 inhibitor sold separately as Tradjenta) with metformin in a single twice-daily pill. Jentadueto XR offers once-daily extended-release dosing. The combination delivers A1C reduction of approximately 1.0 to 1.8 percent with the unique advantage of linagliptin’s complete renal flexibility — no dose adjustment is needed for any level of kidney impairment.
What Jentadueto Contains
Jentadueto is co-marketed by Boehringer Ingelheim and Eli Lilly. Active ingredients:
- Linagliptin — a DPP-4 inhibitor that prolongs the activity of incretin hormones GLP-1 and GIP, enhancing glucose-dependent insulin release and suppressing glucagon after meals. Unique among DPP-4 inhibitors in being eliminated primarily through bile rather than the kidneys, requiring no dose adjustment for renal impairment.
- Metformin hydrochloride — a biguanide that reduces hepatic glucose production, modestly improves insulin sensitivity, and slows intestinal glucose absorption. Foundational first-line type 2 diabetes therapy.
The combination targets two distinct mechanisms — the incretin axis and hepatic glucose output — giving additive glucose lowering with minimal mechanistic overlap.
Available Strengths
| Product | Linagliptin | Metformin | Frequency |
|---|---|---|---|
| Jentadueto 2.5/500 | 2.5 mg | 500 mg (immediate-release) | Twice daily with meals |
| Jentadueto 2.5/850 | 2.5 mg | 850 mg (immediate-release) | Twice daily with meals |
| Jentadueto 2.5/1000 | 2.5 mg | 1,000 mg (immediate-release) | Twice daily with meals |
| Jentadueto XR 2.5/1000 | 2.5 mg | 1,000 mg (extended-release) | Once daily (two tablets with evening meal) |
| Jentadueto XR 5/1000 | 5 mg | 1,000 mg (extended-release) | Once daily (one tablet with evening meal) |
Maximum daily dose is linagliptin 5 mg plus metformin 2,000 mg.
Dosing Instructions
- Jentadueto (immediate-release): take one tablet twice daily with meals to minimize gastrointestinal side effects.
- Jentadueto XR: take once daily with the evening meal. Swallow whole — do not crush, split, or chew.
- If a dose is missed and it is still the same day, take it as soon as remembered with food. Skip if it is close to the next dose.
- Maintain adequate hydration throughout the day.
Who Jentadueto Is For
Jentadueto is approved for adults with type 2 diabetes as an adjunct to diet and exercise. Common scenarios:
- A1C remains above goal despite metformin monotherapy
- Patient already takes linagliptin (Tradjenta) and metformin separately and wants to consolidate
- Mild to moderate chronic kidney disease where Janumet would require sitagliptin dose reduction
- Weight gain from other agents needs to be avoided (linagliptin is weight-neutral)
- Low hypoglycemia risk is desired
It is not approved for type 1 diabetes, diabetic ketoacidosis, or pediatric use.
How Well Jentadueto Works
Pooled data from registration trials show:
- A1C reduction: approximately 1.0 to 1.8 percent in patients with poorly controlled type 2 diabetes (baseline A1C above 8.5 percent).
- Weight change: approximately neutral — linagliptin is weight-neutral, metformin contributes a 1 to 2 kg loss in some patients.
- Fasting glucose: reduction of 25 to 45 mg/dL.
- Hypoglycemia risk: low when used without insulin or sulfonylureas.
- Cardiovascular safety: the CARMELINA trial of linagliptin in 6,979 patients with type 2 diabetes plus cardiovascular and kidney disease showed cardiovascular non-inferiority and, crucially, no heart failure signal.
- Kidney safety: CARMELINA also showed no adverse renal outcomes signal, supporting linagliptin’s use in CKD.
Side Effects
| Side Effect | Source | Approximate Frequency |
|---|---|---|
| Nasopharyngitis | Linagliptin | 5 to 6 percent |
| Upper respiratory infections | Linagliptin | 5 to 7 percent |
| Diarrhea, nausea, abdominal pain | Metformin | 10 to 25 percent (often transient) |
| Headache | Both | 3 to 5 percent |
| Cough | Linagliptin | 3 percent |
| Metallic taste | Metformin | 3 percent |
| Vitamin B12 deficiency | Metformin (long-term) | 5 to 10 percent at 5+ years |
| Hypoglycemia (with insulin/sulfonylureas) | Both | Variable |
| Pancreatitis | Linagliptin | Rare (less than 0.5 percent) |
| Severe joint pain | Linagliptin (class effect) | Rare |
| Bullous pemphigoid | Linagliptin (class effect) | Very rare |
| Lactic acidosis | Metformin | Very rare (3 to 10 per 100,000) |
Gastrointestinal symptoms from metformin typically improve within 2 to 4 weeks of starting, or after switching to Jentadueto XR.
Contraindications and Warnings
- eGFR less than 30 mL/min/1.73 m squared: contraindicated due to metformin lactic acidosis risk (linagliptin alone could continue, but combination cannot).
- eGFR 30 to 45: existing users may continue with caution; do not initiate.
- Active diabetic ketoacidosis or type 1 diabetes.
- Severe hepatic impairment, acute or chronic metabolic acidosis, or chronic alcoholism.
- History of pancreatitis: use cautiously.
- Hold around iodinated contrast and major surgery (48 hours before and after).
- Pregnancy: not recommended in second or third trimester.
Drug Interactions
- Strong CYP3A4 and P-gp inducers (rifampin, carbamazepine, phenytoin, St. John’s wort) can reduce linagliptin levels — combination is not recommended.
- Cationic drugs (cimetidine, dolutegravir, ranolazine) can increase metformin levels.
- Insulin and sulfonylureas increase hypoglycemia risk; doses may need reduction.
- Iodinated contrast: hold Jentadueto 48 hours before and after.
- Alcohol: increases lactic acidosis and hypoglycemia risk.
Cost and Insurance
Without insurance, Jentadueto retails for approximately $500 to $700 per month at U.S. pharmacies. Boehringer Ingelheim and Lilly’s manufacturer copay savings card can reduce eligible commercially insured patients’ out-of-pocket cost to as little as $10 per month for up to 24 months. Medicare and Medicaid patients are not eligible for the savings card but may qualify for income-based patient assistance.
Storage
- Store at controlled room temperature 68 to 77 degrees F (20 to 25 degrees C).
- Keep in original blister or bottle until use.
- Protect from moisture and heat.
- Do not crush, split, or chew Jentadueto XR.
Jentadueto vs Other DPP-4 + Metformin Combinations
| Feature | Jentadueto | Janumet | Kombiglyze XR |
|---|---|---|---|
| DPP-4 inhibitor | Linagliptin 2.5 mg BID or 5 mg QD | Sitagliptin 50 mg BID or 100 mg QD | Saxagliptin 2.5 to 5 mg QD |
| DPP-4 renal adjustment | None needed | Reduce below eGFR 45 | Reduce below eGFR 45 |
| Heart failure signal | No (CARMELINA neutral) | No (TECOS neutral) | Yes (SAVOR signal) |
| Dosing frequency | BID (IR) or QD (XR) | BID (IR) or QD (XR) | QD only |
| Generic availability | No (patent through 2026+) | Generic expected 2026 | No |
Jentadueto’s main advantage is renal flexibility — linagliptin needs no dose adjustment at any eGFR, while sitagliptin and saxagliptin both require reductions in chronic kidney disease. For patients with established or progressing CKD, Jentadueto is the preferred DPP-4 + metformin combination until eGFR drops below 30 and metformin itself must be stopped.
Place in Modern Type 2 Diabetes Care
ADA Standards of Care 2024 recommend DPP-4 inhibitors when weight-neutral, low-hypoglycemia oral therapy is desired and cardiovascular or kidney outcome benefits are not the priority. Jentadueto fits this niche reliably, with the added advantage of complete renal dosing flexibility. For patients with established cardiovascular disease, heart failure, or significant CKD requiring outcome benefits, SGLT2 inhibitor combinations like Synjardy or Xigduo XR are preferred. For broader context, see our type 2 diabetes treatment options.
The Renal-Friendly Advantage in Detail
Approximately 30 to 40 percent of patients with type 2 diabetes will develop chronic kidney disease over a 15-year span. As eGFR declines, dose adjustments become necessary for most diabetes medications. Linagliptin’s biliary elimination means:
- eGFR above 60: standard dose, no adjustment
- eGFR 45 to 60: standard dose, no adjustment
- eGFR 30 to 45: standard dose, no adjustment (though metformin component may need reduction)
- eGFR below 30: linagliptin remains safe; metformin must be stopped, so switch to single-agent Tradjenta
- End-stage renal disease on dialysis: linagliptin 5 mg daily remains safe
This profile makes linagliptin particularly valuable for older patients with declining renal function and for those who want one fewer medication change as kidney disease progresses.
Practical Considerations
- Take Jentadueto IR with breakfast and dinner; Jentadueto XR with dinner only.
- Expect the linagliptin effect on top of metformin to appear within 8 to 12 weeks.
- Stop and call your clinician for severe abdominal pain radiating to the back, persistent vomiting, or jaundice — symptoms of pancreatitis.
- Watch for severe, persistent joint pain — although rare, this is a class effect of DPP-4 inhibitors that can require switching.
- Inform any new clinician about Jentadueto, particularly before contrast imaging or surgery.
- Discuss vitamin B12 testing every 1 to 2 years if you have been on metformin long-term.
Jentadueto and Weight
Jentadueto is approximately weight-neutral, similar to Janumet. Linagliptin causes no weight change, and metformin may produce modest weight loss of 1 to 2 kg. For larger weight loss, GLP-1 receptor agonists or SGLT2 inhibitors are more effective. Read our overview of treatment options for context on weight-active alternatives.
Jentadueto in Prediabetes
Jentadueto is not approved for prediabetes. Metformin alone is sometimes used off-label for high-risk individuals with prediabetes, but DPP-4 inhibitors are reserved for type 2 diabetes. Lifestyle modification and weight loss are first-line. See our discussion of whether prediabetes is reversible for context.
The Bottom Line
Jentadueto combines linagliptin and metformin in a single twice-daily tablet (or once-daily Jentadueto XR) for adults with type 2 diabetes. Combined A1C reduction of 1.0 to 1.8 percent comes with weight neutrality, low hypoglycemia risk, and the cardiovascular safety established in CARMELINA. Linagliptin’s renal flexibility — no dose adjustment at any eGFR — makes Jentadueto the preferred DPP-4 + metformin combination for patients with chronic kidney disease until eGFR drops below 30 and metformin itself must be stopped. Common side effects are mild upper respiratory and gastrointestinal symptoms. Talk to your clinician about whether Jentadueto’s profile fits your kidney function and overall diabetes plan, especially compared with sitagliptin-based Janumet or SGLT2-containing combinations.
